Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 5/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621911 | 0.83 | MEN1 (0.45) | NR1H3NR1H2ALPLMEN1KMT2A | |
| SCHEMBL6623565 | 0.82 | ALPL (0.39) | NR1H3NR1H2ALPLGRM5ALDH1A1 | |
| SCHEMBL6618057 | 0.81 | CYP2D6 (0.50) | NR1H3NR1H2ALDH1A1TDP1KDM4E | |
| SCHEMBL6676243 | 0.77 | NR1H3 (0.57) | NR1H3NR1H2MEN1KMT2AALDH1A1 | |
| SCHEMBL7221234 | 0.72 | HTR7 (0.57) | — | |
| SCHEMBL9395192 | 0.72 | NR1H3 (0.47) | NR1H3NR1H2ALPLMEN1KMT2A | |
| SCHEMBL9937910 | 0.70 | CA2 (0.48) | ALDH1A1KDM4E | |
| SCHEMBL68721 | 0.68 | ALDH1A1 (0.45) | NR1H3ALPLMEN1KMT2AALDH1A1 | |
| SCHEMBL31439009 | 0.68 | KDM4E (0.57) | NR1H3NR1H2ALPLMEN1KMT2A | |
| SCHEMBL7229895 | 0.68 | CYP1A1 (0.46) | MEN1KMT2AALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891332-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0891332-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036871-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | NR1H3 895/4885NR1H2 740/4885ALPL 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.